Phase 1 Dose-Escalation Study of LY2157299 Monotherapy in Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2016
At a glance
- Drugs Galunisertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 30 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 May 2014 Planned End Date changed from 1 Apr 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 05 Feb 2014 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.